BioStock: Abliva’s CEO about the phase II study

In December last year, Abliva initiated a potentially pivotal phase II study with KL1333. The candidate is being developed for the treatment of primary mitochondrial disease in adults, a group of rare diseases that lack effective treatment. CEO Ellen K. Donnelly visited BioStock’s studio to tell us more.

See the full interview at biostock.se:

https://www.biostock.se/en/2023/03/ablivas-ceo-about-the-phase-ii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se